The 2022 Scopus CiteScore of Cancer Drug Resistance 

The 2022 citation metrics have been officially released in Scopus!

We are pleased to announce that the CiteScore of our journal, Cancer Drug Resistance, has increased from 3.7 to 5.5, placing it in the top 30% of journals in the "Pharmacology (medical)" category and the top 50% of journals in the "Cancer Research" category within Scopus. This means that our journal is already at the top of Q2 in "Pharmacology(medical)" category.

We would like to extend our sincere gratitude to all who have contributed to the success of Cancer Drug Resistance, including our esteemed Editorial Board members, Guest Editors, authors, reviewers, and loyal readers. Your unwavering support has been crucial in driving the journal's progress.

This remarkable achievement reinforces our commitment to building a platform for publishing valuable academic findings that promote innovation and advance scientific research in the field of cancer drug resistance.

Once again, we express our appreciation to everyone involved in this accomplishment and eagerly anticipate further collaborations and future successes.